Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAPLE
2024-515049-41-00Phase 2Authorised
- Sponsor
- University of Turin
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by University of Turin. Primary endpoint: Radiological progression-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-515049-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515049-41-00.